%0 Journal Article %T 阿托伐他汀联合曲美他嗪治疗冠心病心绞痛的疗效观察 %T Clinical effect of atorvastatin on coronary heart disease and angina pectoris %A 黄忠力,黄燕春,黎 明 %A HUANG,Zhong li %A HUANG,Yan chun %A LI,Ming %J 中国临床新医学 %J CHINESE JOURNAL OF NEW CLINICAL MEDICINE %@ 1674-3806 %V 11 %N 9 %D 2018 %P 922-925 %K 阿托伐他汀;冠心病心绞痛;疗效 %K Atorvastatin;Angina pectoris;Efficacy %X [摘要] 目的 观察阿托伐他汀治疗冠心病心绞痛的疗效。方法 选取2016-01~2017-04收治的120例冠心病心绞痛患者,采用随机数字表法将研究对象分为观察组和对照组,各60例。对照组单纯应用曲美他嗪治疗,观察组在对照组基础上加用阿托伐他汀治疗,两组均治疗2个月。比较两组治疗效果及治疗前后血脂指标、血清超敏C反应蛋白(hs-CRP)、B型钠尿肽(BNP)水平和不良反应发生率。结果 观察组显效33例,有效23例,无效4例。对照组显效24例,有效23例,无效13例。观察组临床疗效优于对照组(P<0.05)。观察组治疗后LDL-C、TG、TC水平均低于对照组,HDL-C水平高于对照组(P<0.05)。观察组治疗后血清hs-CRP及BNP水平均低于对照组(P<0.05)。观察组不良反应发生率为8.3%,与对照组(11.7%)比较差异无统计学意义(P>0.05)。结论 应用阿托伐他汀治疗冠心病心绞痛能够显著提高疗效及调节血脂水平,值得临床推广。 %X [Abstract] Objective To study the clinical effect of atorvastatin on coronary heart disease and angina pectoris. Methods One hundred and twenty patients with coronary heart disease and angina pectoris were enrolled in our hospital from January 2016 to April 2017. The patients were divided into control group and observation group by random number method. The control group was given trimetazidine treatment. The observation group was treated with atorvastatin plus trimetazidine. All the patients were treated for two months. The total effective rate, the incidence of adverse reactions, the levels of serum lipids, serum high sensitivity C-reactive protein(hs-CRP) and brain natriuretic peptide(BNP) were compared between the two groups. Results 33 cases of observation group marked effectivness, 23 cases effectivness and 4 cases failuer, 24 cases of control group merked effectivness, 23 cases effectivness and 13 case failuer. The total effective rate in the observation group was significantly higher than that in the control group(P<0.05). After treatment, the levels of LDL-C, TG and TC in the observation group were significantly lower than those in the control group, and HDL-C in the observation group was significantly higher than that in the control group(P<0.05). The levels of serum hs-CRP and BNP in the observation group were significantly lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Atorvastatin can effectively regulate blood lipid levels and has a significant effect on patients with coronary heart disease and angina pectoris. %R 10.3969/j.issn.1674-3806.2018.09.21 %U http://www.zglcxyxzz.com/ch/reader/view_abstract.aspx %1 JIS Version 3.0.0